Modality
Multispecific
MOA
HER2
Target
FLT3
Pathway
Innate Imm
DLBCLAMLCF
Development Pipeline
Preclinical
~Jan 2010
→ ~Apr 2011
Phase 1
~Jul 2011
→ ~Oct 2012
Phase 2
~Jan 2013
→ ~Apr 2014
Phase 3
~Jul 2014
→ ~Oct 2015
NDA/BLA
~Jan 2016
→ ~Apr 2017
Approved
Jul 2017
→ Aug 2031
ApprovedCurrent
NCT08763510
1,132 pts·AML
2017-07→2031-08·Not yet recruiting
1,132 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2031-08-275.4y awayPh3 Readout· AML
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
Approved
Not yet…
Catalysts
Ph3 Readout
2031-08-27 · 5.4y away
AML
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08763510 | Approved | AML | Not yet recr... | 1132 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| Sotorapivir | Moderna | Approved | FLT3 | |
| Nidaratamab | Exelixis | Phase 3 | FLT3 | |
| Voxaderotide | Viking Therapeutics | Approved | PD-L1 | |
| Adagrarapivir | Ideaya Bio | Phase 1/2 | IL-17A |